Often dubbed the "Masters of the Universe," Goldman Sachs is the elite and clandestine top-tier investment bank that’s had a hand in some of the largest and most notable deals on Wall Street.

Whales with a lot of money to spend have taken a noticeably bullish stance on Goldman Sachs Gr. Looking at options history for Goldman Sachs Gr (NYSE:GS) we detected 21 trades. If we consider the ...

Deep-pocketed investors have adopted a bearish approach towards Goldman Sachs Gr (NYSE:GS), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga ...

DALLAS, Jan. 30, 2025 /PRNewswire/ -- Goldman Sachs Alternatives and Dalfen Industrial, a leader in last-mile industrial real estate, have announced the acquisition of a 21-building, 2.1-million ...

Goldman Sachs Asset Management (GSAM) is a world-renowned company that has been providing investment management, portfolio design and advisory services to individual and institutional investors ...

Fintel reports that on January 31, 2025, Goldman Sachs downgraded their outlook for Occidental Petroleum (LSE:0KAK) from Neutral to Sell. As of January 28, 2025, the average one-year price target ...

Goldman Sachs (GS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.

Fintel reports that on January 31, 2025, Goldman Sachs downgraded their outlook for Occidental Petroleum (WBAG:OXYP) from Neutral to Sell. There are 1,826 funds or institutions reporting positions ...

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (WBAG:MRNA) from Buy to Neutral. There are 1,449 funds or institutions reporting positions in Moderna.

Fintel reports that on January 30, 2025, Goldman Sachs upgraded their outlook for RH (LSE:0KTF) from Sell to Neutral. There are 794 funds or institutions reporting positions in RH. This is an ...

Fintel reports that on January 29, 2025, Goldman Sachs downgraded their outlook for Moderna (XTRA:0QF) from Buy to Neutral. As of January 28, 2025, the average one-year price target for Moderna is ...